Repligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Repligen Co. (NASDAQ:RGENGet Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $197.75.

A number of analysts have recently weighed in on RGEN shares. KeyCorp boosted their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus boosted their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd.

Read Our Latest Report on Repligen

Repligen Price Performance

NASDAQ RGEN opened at $163.34 on Tuesday. The company has a 50 day moving average price of $177.42 and a two-hundred day moving average price of $175.54. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $110.45 and a 12-month high of $211.13. The stock has a market capitalization of $9.13 billion, a PE ratio of 653.39, a price-to-earnings-growth ratio of 5.57 and a beta of 1.03.

Repligen (NASDAQ:RGENGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. During the same quarter in the previous year, the firm posted $0.64 earnings per share. Repligen’s quarterly revenue was down 17.1% compared to the same quarter last year. As a group, equities analysts predict that Repligen will post 1.46 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock valued at $5,039,532 over the last quarter. 1.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. YHB Investment Advisors Inc. bought a new position in Repligen in the first quarter valued at $26,000. Benjamin F. Edwards & Company Inc. grew its position in Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares in the last quarter. Signaturefd LLC grew its position in Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 86 shares in the last quarter. Principal Securities Inc. bought a new position in Repligen in the fourth quarter valued at $48,000. Finally, Milestone Investment Advisors LLC bought a new position in Repligen in the third quarter valued at $61,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

(Get Free Report

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Articles

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.